Navigating RSV protection this fall

Everything we learned the past year

Last year was the first time we had RSV vaccines and preventive monoclonal antibodies for a subset of people—pregnant women, older adults, and babies. This is a huge deal, as RSV poses a massive burden on health, health systems, and individuals every year.

While clinical trial data blew expectations out of the water, “real-world” data after a vaccine rol…